Jim Cassella

Company: Concert Pharmaceuticals

Job title: Chief Development Officer

Seminars:

Long-Term Dosing with an Oral JAK Inhibitor for Moderate to Severe Alopecia Areata: Safety & Efficacy Update for CTP-543 9:30 am

Examining how JAK inhibitors represent a potentially-important mechanism for the treatment of alopecia areata (AA), a serious autoimmune hair-loss disorder with unmet need. Exploring CTP-543 a selective JAK1 and JAK2 inhibitor currently in Phase 3 trials, which has successfully regrown hair in multiple Phase 2 trials and most eligible trial patients have rolled over into…Read more

day: Day Two